Is Philip Morris Stock Overvalued?
If there is one industry that can be termed truly…
Sell
26
ITRM Quote, Financials, Valuation and Earnings
Last price:
$1.52
Seasonality move
:
-6.06%
Day range:
$1.51 - $1.58
52-week range:
$0.81 - $3.02
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
38.43x
P/B ratio:
--
Volume:
400.2K
Avg. volume:
1.1M
1-year change:
-20%
Market cap:
$25.2M
Revenue:
--
EPS (TTM):
-$2.65
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Iterum Therapeutics PLC has 393.42% upside to fair value with a price target of $6.50 per share.
ITRM vs. S&P 500
-
Over the past 5 trading days, Iterum Therapeutics PLC has underperformed the S&P 500 by -9.03% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Iterum Therapeutics PLC does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Iterum Therapeutics PLC revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Iterum Therapeutics PLC reported revenues of --.
Earnings Growth
-
Iterum Therapeutics PLC has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Iterum Therapeutics PLC reported earnings per share of -$0.46.
Enterprise value:
33.1M
EV / Invested capital:
--
Price / LTM sales:
38.43x
EV / EBIT:
--
EV / Revenue:
46.29x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.94x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$29.3M | -$44M | -$26.5M | -$16.7M | -$4.9M | |
| EBITDA | -$36.8M | -$27.8M | -$27.7M | -$3M | -$5.4M | |
| Diluted EPS | -$3.00 | -$2.27 | -$1.71 | -$0.30 | -$0.30 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $12.1M | $90.2M | $66.7M | $38.5M | $15.9M | |
| Total Assets | $26.3M | $98.4M | $71.6M | $39.7M | $15.9M | |
| Current Liabilities | $40.9M | $17.8M | $7.5M | $16.4M | $18.7M | |
| Total Liabilities | $82.2M | $46M | $39M | $36.3M | $27.4M | |
| Total Equity | -$55.9M | $52.4M | $32.5M | $3.4M | -$11.5M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$16.7M | -$30.8M | -$35.4M | -$9.3M | -$2.7M | |
| Cash From Investing | $5.1M | $14.2M | $30.6M | $360K | $5.7M | |
| Cash From Financing | -$3.9M | $878K | $13.4M | $10K | $5.4M | |
| Free Cash Flow | -$16.7M | -$30.8M | -$35.4M | -$9.3M | -$2.7M | |
ITRM
Sector
Market Cap
$25.2M
$45.7M
Price % of 52-Week High
50.33%
47.48%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.75%
1-Year Price Total Return
-20%
-32.34%
Beta (5-Year)
2.327
0.746
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$1.61
200-day SMA
Buy
Level
$1.42
Bollinger Bands (100)
Buy
Level
1.02 - 1.92
Chaikin Money Flow
Sell
Level
-518.1M
20-day SMA
Sell
Level
$1.75
Relative Strength Index (RSI14)
Sell
Level
38.68
ADX Line
Sell
Level
20.85
Williams %R
Buy
Level
-92.0635
50-day SMA
Sell
Level
$1.82
MACD (12, 26)
Sell
Level
-0.09
25-day Aroon Oscillator
Sell
Level
-92
On Balance Volume
Neutral
Level
583.3M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (5)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Iterum Therapeutics PLC is a clinical-stage pharmaceutical company. The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally. Its sulopenem program has the potential to offer a solution to the problem of antibiotic resistance and the toxicity limitations of existing agents. The company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
Stock Forecast FAQ
In the current month, ITRM has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ITRM average analyst price target in the past 3 months is $6.50.
-
Where Will Iterum Therapeutics PLC Stock Be In 1 Year?
According to analysts, the consensus estimate is that Iterum Therapeutics PLC share price will rise to $6.50 per share over the next 12 months.
-
What Do Analysts Say About Iterum Therapeutics PLC?
Analysts are divided on their view about Iterum Therapeutics PLC share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Iterum Therapeutics PLC is a Sell and believe this share price will drop from its current level to $6.00.
-
What Is Iterum Therapeutics PLC's Price Target?
The price target for Iterum Therapeutics PLC over the next 1-year time period is forecast to be $6.50 according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ITRM A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Iterum Therapeutics PLC is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of ITRM?
You can purchase shares of Iterum Therapeutics PLC via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Iterum Therapeutics PLC shares.
-
What Is The Iterum Therapeutics PLC Share Price Today?
Iterum Therapeutics PLC was last trading at $1.52 per share. This represents the most recent stock quote for Iterum Therapeutics PLC. Yesterday, Iterum Therapeutics PLC closed at $1.52 per share.
-
How To Buy Iterum Therapeutics PLC Stock Online?
In order to purchase Iterum Therapeutics PLC stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Quantum Stocks Should I Buy?
The last several years have seen a series of tech…
Will Sirius XM Be a 10-Bagger Stock?
Last year, Warren Buffett surprised practically everyone when he acquired…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
32
FTAI alert for Jan 22
FTAI Aviation [FTAI] is up 1.44% over the past day.
Sell
2
EDU alert for Jan 22
New Oriental Education & Technology Group [EDU] is down 0.47% over the past day.
Buy
51
GH alert for Jan 22
Guardant Health [GH] is up 7.6% over the past day.
